Compassionate Use Narsoplimab for Severe Refractory Transplantation-Associated Thrombotic Microangiopathy in Children

血栓性微血管病 伊库利珠单抗 医学 降纤酶 耐火材料(行星科学) 补体系统 内科学 造血干细胞移植 钙调神经磷酸酶 移植 非典型溶血尿毒综合征 胃肠病学 免疫学 抗体 物理 疾病 天体生物学
作者
Michelle Long Schoettler,Seema R. Patel,Elyse Bryson,Laura Deeb,Benjamin Watkins,Muna Qayed,Shanmuganathan Chandrakasan,Taylor Fitch,Katherine Silvis,Jayre A Jones,Satheesh Chonat,Kirsten M. Williams
标识
DOI:10.1016/j.jtct.2023.12.017
摘要

Transplant-associated thrombotic microangiopathy (TA-TMA) is a common and potentially severe complication of hematopoietic cell transplantation. TA-TMA-directed therapy with eculizumab, a complement C5 inhibitor, has resulted in a survival benefit in some studies. However, children with TA-TMA refractory to C5 inhibition with eculizumab (rTA-TMA) have mortality rates exceeding 80%, and there are no other known therapies. Narsoplimab, an inhibitor of the MASP-2 effector enzyme of the lectin pathway, has been studied in adults with TA-TMA as first-line therapy with a response rate of 61%. Although there are limited data on narsoplimab use as a second-line agent in children, we hypothesized, that complement pathways proximal to C5 are activated in rTA-TMA, and that narsoplimab may ameliorate rTA-TMA in children. In this single-center study, children were enrolled on single-patient, Institutional Review Board-approved compassionate use protocols for narsoplimab treatment. Clinical complement lab tests were obtained at the discretion of the treating physician, although all patients were also offered participation in a companion biomarker study. Research blood samples were obtained at the time of TA-TMA diagnosis, prior to eculizumab treatment, at the time of refractory TA-TMA diagnosis prior to the first narsoplimab dose, and 2 weeks after the first narsoplimab dose. Single ELISA kits were used to measure markers of complement activation according to the manufacture's instructions. Five children with rTA-TMA received narsoplimab; 3 were in multiorgan failure and 2 had worsening multiorgan dysfunction at the time of treatment. Additional comorbidities at the time of treatment included sinusoidal obstructive syndrome (SOS; n = 3), viral infection (n = 3), and steroid-refractory stage 4 lower gut grade IV acute graft-versus-host disease (aGVHD, n = 3). Two infants with concurrent SOS and no aGVHD had resolution of organ dysfunction; 1 also developed transfusion-independence (complete response), and the other's hematologic response was not assessable in the setting of leukemia and chemotherapy (partial response). One additional patient achieved transfusion independence but had no improvement in organ manifestations (partial response), and 2 patients treated late in the course of disease had no response. Narsoplimab was well tolerated without any attributed adverse effects. Three patients consented to provide additional research blood samples. One patient with resolution of organ failure demonstrated evidence of proximal pathway activation prior to narsoplimab treatment with subsequent declines in Ba, Bb, C3a, and C5a and increases in C3 in both clinical and research lab tests. Otherwise, there was no clear pattern of other complement markers, including MASP-2 levels, after therapy. In this cohort of ill children with rTA-TMA and multiple comorbidities, 3 patients benefited from narsoplimab. Notably, the 2 patients with resolution of organ involvement did not have steroid-refractory aGVHD, which is thought to be a critical driver of TA-TMA. Additional studies are needed to determine which patients are most likely to benefit from narsoplimab and which markers may be most helpful for monitoring lectin pathway activation and inhibition.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
现代小丸子完成签到 ,获得积分10
2秒前
缺水哥完成签到,获得积分10
2秒前
缺水哥发布了新的文献求助10
5秒前
1234发布了新的文献求助10
5秒前
1762120完成签到,获得积分10
5秒前
ZR关闭了ZR文献求助
7秒前
卖萌的秋田完成签到,获得积分10
7秒前
热情铭完成签到 ,获得积分10
8秒前
完美麦片完成签到,获得积分10
13秒前
lll完成签到,获得积分10
14秒前
务实鞅完成签到 ,获得积分10
15秒前
量子星尘发布了新的文献求助10
20秒前
mawenyu完成签到,获得积分10
21秒前
17完成签到,获得积分20
21秒前
高大的水壶完成签到,获得积分10
22秒前
英俊的铭应助wellyou采纳,获得10
24秒前
风中的向卉完成签到 ,获得积分10
27秒前
Mp4完成签到 ,获得积分10
27秒前
凌兰完成签到 ,获得积分10
27秒前
plain完成签到,获得积分10
28秒前
陌上花开完成签到,获得积分10
29秒前
30秒前
fg2477完成签到,获得积分10
31秒前
忙碌的数学人完成签到,获得积分10
31秒前
情怀应助Engen采纳,获得10
31秒前
HJJHJH完成签到,获得积分10
33秒前
Bob发布了新的文献求助10
34秒前
35秒前
36秒前
HJJHJH发布了新的文献求助50
37秒前
JW完成签到,获得积分10
37秒前
wanci应助张参采纳,获得10
38秒前
谦让的西装完成签到 ,获得积分10
39秒前
李演员完成签到,获得积分10
40秒前
fei菲飞完成签到,获得积分10
40秒前
42秒前
Zhaowx完成签到,获得积分10
42秒前
Theprisoners完成签到,获得积分0
42秒前
木子发布了新的文献求助30
42秒前
42秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038235
求助须知:如何正确求助?哪些是违规求助? 3575992
关于积分的说明 11374009
捐赠科研通 3305760
什么是DOI,文献DOI怎么找? 1819276
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022